Company Overview - Acurx Pharmaceuticals, Inc. (ACXP) is part of the Medical sector, which includes 925 individual stocks and currently holds a Zacks Sector Rank of 10 among 16 groups [2] - The company is categorized under the Medical - Biomedical and Genetics industry, which consists of 444 companies and is ranked 140 in the Zacks Industry Rank [6] Performance Metrics - Acurx Pharmaceuticals has returned 93.2% year-to-date, significantly outperforming the average loss of 3.2% in the Medical group [4] - The Zacks Consensus Estimate for ACXP's full-year earnings has increased by 42.5% over the past quarter, indicating a positive trend in analyst sentiment [4] Comparative Analysis - Another stock in the Medical sector, Apyx Medical (APYX), has returned 4.9% year-to-date and has a Zacks Rank of 2 (Buy) [5] - Apyx Medical belongs to the Medical - Products industry, which has seen a decline of 10.3% this year, contrasting with Acurx's strong performance [7]

Summary of Apyx Medical Conference Call Company Overview - **Company**: Apyx Medical - **CEO**: Charlie Goodwin - **Focus**: Surgical aesthetics, specifically through the introduction of AYON technology Key Points Product Development and Market Position - Apyx Medical has developed AYON, a revolutionary integrated system for surgical aesthetics, which received approval in May and began commercial shipping in September [6][8] - AYON is designed to streamline surgical procedures by integrating multiple technologies into one system, allowing surgeons to perform various tasks simultaneously [7][22] - The company aims to dominate the surgical aesthetics market, positioning AYON as a game changer compared to existing technologies like VASER, which has seen no significant innovation in over a decade [5][6] Market Dynamics and Growth Potential - The introduction of GLP-1 drugs has significantly impacted the aesthetics market, leading to increased demand for surgical interventions due to skin laxity from rapid weight loss [16][19] - The market for GLP-1 drugs is projected to grow tenfold by 2030, creating a substantial opportunity for companies like Apyx Medical that can address the resulting aesthetic needs [17][18] - Apyx Medical anticipates a growth rate of 17%-19% for the aesthetics market, with a reported 38% growth in the surgical aesthetics market in Q4, and nearly 50% growth in the U.S. [49] Sales and Customer Engagement - Approximately 80% of AYON sales have come from existing customers upgrading from previous technologies, while 20% are new customers [42] - The list price for AYON is set at $360,000, which is seen as a competitive value proposition compared to the previous Apyx One generator priced at $165,000 [40][41] - The company is actively engaging with top body contouring doctors globally, expanding its customer base significantly [41] Financial Performance - Apyx Medical has reduced operating expenses from $53.8 million three years ago to $39.5 million this year, achieving EBITDA positivity and near break-even on an operating basis in the last quarter [76][79] - The company is on track to achieve cash flow positivity by the end of the year, driven by the successful launch of AYON and efficient cost management [75][79] International Expansion - Apyx Medical is currently selling Renuvion standalone in over 80 countries, with recent registrations in China and Korea, where the aesthetic market is expected to grow [52][61] - The company plans to introduce AYON internationally once it is registered in those markets, leveraging the growing demand for aesthetic procedures [50][52] Competitive Landscape - The aesthetics market is undergoing disruption due to GLP-1 drugs, which may negatively impact companies not aligned with the new patient needs, while benefiting those like Apyx Medical that can adapt [19][20] - Apyx Medical's integrated approach with AYON is expected to attract surgeons looking for efficiency and effectiveness in their practices [22][23] Additional Insights - The company emphasizes the importance of a strong sales force, with a focus on attracting high-caliber talent from the aesthetic space to drive sales of AYON [63][65] - AYON's design allows for a more organized and efficient operating room setup, which is particularly beneficial in smaller surgical environments [22][23] This summary encapsulates the key insights from the Apyx Medical conference call, highlighting the company's innovative product offerings, market dynamics, financial performance, and strategic growth plans.

Management View - Apyx Medical Corporation reported a record revenue of $19.2 million for Q4 2025, marking a significant achievement for the company [2] - The revenue growth was primarily driven by a 38% increase in surgical aesthetics product sales, which reached $16.7 million, largely attributed to the launch of the AYON body contouring product [2] Future Outlook - Apyx Medical has set a revenue growth target of 9%–11% for 2026, indicating confidence in the continued acceleration of the AYON product line [2]

Financial Data and Key Metrics Changes - The company reported record revenue of $19.2 million for Q4 2025, a 35% increase from $14.2 million in the same period last year [7][26] - Gross profit for Q4 2025 increased to $12 million, with a gross profit margin of 62.6%, slightly down from 63% in the prior year [30] - Net loss attributable to stockholders was $1.3 million or $0.03 per share for Q4 2025, compared to a net loss of $4.6 million or $0.12 per share in the prior year [32] Business Line Data and Key Metrics Changes - Revenue from the surgical aesthetics segment increased 38% to $16.7 million in Q4 2025, driven by sales of the AYON body contouring system [27][28] - OEM segment sales increased 16% to $2.5 million in Q4 2025, attributed to increased sales volume to existing customers [29] Market Data and Key Metrics Changes - Domestic revenue increased 42% year-over-year to $15 million, while international revenue increased 15% year-over-year to $4.2 million [29] - The company noted a significant shift in the market driven by the adoption of GLP-1 drugs for weight loss, leading to increased demand for aesthetic treatments [17][19] Company Strategy and Development Direction - The company is focused on expanding the AYON platform and enhancing its market position by submitting a follow-up application for power liposuction, expected to receive clearance in mid-2026 [14][15] - Apyx Medical is strengthening its commercial organization by acquiring high-caliber sales talent to support growth and market share [21][68] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the market's reaction to AYON, indicating that the adoption curve is still in the early stages and that the company is well-positioned to capitalize on market shifts [11][20] - The company anticipates total revenue for 2026 to be in the range of $57.5 million to $58.5 million, reflecting a 9%-11% increase compared to 2025 [36] Other Important Information - Cash used in operating activities decreased to $2.5 million in Q4 2025 from $2.9 million in the prior year, with total cash burn for the year decreasing to $8 million from $18.7 million [33][34] - The company had cash and cash equivalents of $31.7 million as of December 31, 2025, and expects to maintain cash flow through 2027 [35] Q&A Session Summary Question: Can you provide more details on handpiece and capital equipment sales? - Management indicated that growth in Q4 was driven by AYON, with domestic sales growing almost 50% [50] Question: What is the pricing strategy for AYON? - The list price of AYON is approximately $360,000, which includes the Apyx One generator and complementary components [53] Question: What feedback have you received from customers regarding AYON? - Customers have expressed strong satisfaction with AYON, with requests for the power-assisted handpiece expected in the first half of the year [58] Question: What are the plans for AYON's international expansion? - Currently, AYON is approved only in the U.S., with plans to register in key countries like Europe and Brazil [74] Question: What is the expected cash flow situation moving forward? - The company plans to be cash flow positive no later than Q4 2026 [83]

Financial Data and Key Metrics Changes - The company reported record revenue of $19.2 million for Q4 2025, a 35% increase from $14.2 million in the same period last year [6][25] - Gross profit for Q4 2025 increased to $12 million compared to $9 million in the prior year, while gross profit margin slightly decreased to 62.6% from 63% [29] - Net loss attributable to stockholders was $1.3 million or $0.03 per share for Q4 2025, compared to a net loss of $4.6 million or $0.12 per share in the prior year [31] Business Line Data and Key Metrics Changes - Revenue for the surgical aesthetics segment increased 38% to $16.7 million in Q4 2025, driven by sales of the AYON body contouring system [26][27] - OEM segment sales increased 16% to $2.5 million in Q4 2025, attributed to increased sales volume to existing customers [28] Market Data and Key Metrics Changes - Domestic revenue increased 42% year-over-year to $15 million, while international revenue increased 15% year-over-year to $4.2 million [28] - The market for aesthetic surgery is evolving, with a notable increase in demand driven by the adoption of GLP-1 drugs for weight loss, leading to increased interest in body contouring treatments [16][18] Company Strategy and Development Direction - The company is focused on expanding the AYON platform and enhancing its market position by acquiring high-caliber sales talent [21][65] - Plans to submit for regulatory approvals in key international markets, including Europe and Brazil, are underway to expand AYON's reach [71] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong market demand for AYON and the potential for significant growth in the aesthetic surgery market [9][20] - The company anticipates total revenue for 2026 to be in the range of $57.5 million to $58.5 million, reflecting a 9%-11% increase compared to 2025 [35] Other Important Information - Cash used in operating activities decreased to $2.5 million in Q4 2025 from $2.9 million in the prior year, and for the full year, cash used decreased to $8 million from $18.7 million [32][33] - The company expects to achieve cash flow positivity no later than Q4 2026 [80] Q&A Session Summary Question: Can you provide more details on handpiece and capital equipment sales? - Management indicated that growth in Q4 was driven by AYON, with domestic sales growing nearly 50% [47] Question: What is the pricing strategy for AYON? - The list price for AYON is approximately $360,000, which includes the Apyx One generator and complementary components [50] Question: What feedback have you received from customers regarding AYON? - Customers have expressed strong satisfaction with AYON, with requests for the power-assisted handpiece expected in the first half of the year [54] Question: How are new salespeople being integrated into the company? - The company is leveraging the strength of AYON to attract top sales talent and is focusing on expanding market share [62][65] Question: What are the plans for AYON's international expansion? - Currently approved only in the U.S., the company plans to register AYON in key international markets, including Europe and Brazil [71]

Financial Data and Key Metrics Changes - The company reported record revenue of $19.2 million for Q4 2025, a 35% increase from $14.2 million in the same period last year [5][16] - Gross profit for Q4 2025 increased to $12 million compared to $9 million in the prior year, while gross profit margin slightly decreased to 62.6% from 63% [18] - Net loss attributable to stockholders was $1.3 million or $0.03 per share for Q4 2025, compared to a net loss of $4.6 million or $0.12 per share in the prior year [19] Business Line Data and Key Metrics Changes - Revenue from the surgical aesthetics segment increased by 38% to $16.7 million in Q4 2025, driven primarily by sales of the AYON body contouring system [6][16] - The OEM segment saw a 16% increase in sales to $2.5 million for Q4 2025, attributed to increased sales volume to existing customers [17] Market Data and Key Metrics Changes - Domestic revenue increased by 42% year-over-year to $15 million, while international revenue increased by 15% year-over-year to $4.2 million [17] - The company noted a significant shift in the aesthetics market driven by the adoption of GLP-1 drugs for weight loss, leading to increased demand for body contouring treatments [12][13] Company Strategy and Development Direction - The company plans to focus resources on the surgical aesthetics segment, expecting revenue in this segment to reach $53 million-$54 million in 2026, reflecting a 17%-19% increase compared to 2025 [21] - The company is actively strengthening its commercial organization by acquiring high-caliber sales talent to support growth and market share [14][43] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the market reception of AYON, indicating that the adoption curve is still in the early stages and that the product has exceeded expectations [8][36] - The company anticipates achieving market clearance for power liposuction in mid-2026, which is expected to further enhance AYON's market position [10] Other Important Information - Cash used in operating activities decreased to $2.5 million in Q4 2025 from $2.9 million in the prior year, and for the full year, cash used decreased to $8 million from $18.7 million [19][20] - The company expects to be cash flow positive no later than Q4 2026, with cash projected to last through 2027 [20][55] Q&A Session Summary Question: Can you provide more color on handpiece and CapEx sales? - The growth in Q4 was driven by AYON, with domestic sales increasing nearly 50% [24][29] Question: Any pricing commentary on AYON? - The list price of AYON is approximately $360,000, providing a value proposition for doctors [32] Question: What has been going well with AYON six months into the launch? - Customer feedback has been overwhelmingly positive, with requests for the power-assisted handpiece expected in the first half of the year [35][36] Question: How are territories divided for new salespeople? - The company is leveraging the strength of AYON to attract top talent in the industry [42][43] Question: What countries is AYON approved in? - Currently, AYON is approved only in the United States, with plans for registration in key countries like Europe and Brazil [48]

Core Insights - Apyx Medical Corporation reported a record total revenue of $19.2 million for Q4 2025, a 34.7% increase from $14.2 million in Q4 2024, driven by strong demand for the AYON Body Contouring System [4][5][7] - The company anticipates total revenue for FY2026 to be between $57.5 million and $58.5 million, with Surgical Aesthetics revenue projected to be in the range of $53.0 million to $54.0 million [4][20] Financial Performance - Surgical Aesthetics revenue for Q4 2025 was $16.7 million, up 38.1% from $12.1 million in Q4 2024, primarily due to nearly 50% growth in U.S. sales [5][7] - OEM revenue for Q4 2025 was approximately $2.5 million, reflecting a 15.6% increase from $2.1 million in Q4 2024 [5][6] - For the full year 2025, total revenue increased by 9.9% to $52.8 million compared to $48.1 million in 2024 [12][16] Profitability Metrics - Gross profit for Q4 2025 rose to $12.0 million, with a gross margin of 62.6%, slightly down from 63.0% in the prior year [8] - Adjusted EBITDA for Q4 2025 was $0.7 million, a significant improvement from an adjusted EBITDA loss of $2.2 million in Q4 2024 [11][34] - The net loss attributable to stockholders for Q4 2025 was $1.3 million, compared to a net loss of $4.6 million in Q4 2024 [10][34] Operating Expenses - Operating expenses remained flat at $12.0 million for Q4 2025, with minor fluctuations in various expense categories [9] - For the full year 2025, operating expenses decreased to $39.5 million from $48.2 million in 2024, driven by reductions in salaries, administrative, and research expenses [15] Market Position and Product Development - The AYON Body Contouring System, launched in September 2025, is expected to drive significant growth as awareness increases [3][4] - The company submitted a new 510(k) premarket notification to the FDA for AYON's label expansion to include power liposuction, with potential clearance anticipated in mid-2026 [5][21]

Core Viewpoint - Apyx Medical Corporation will release its financial results for the fourth quarter of fiscal year 2025 on March 10, 2026, before market opening [1]. Group 1: Financial Results Announcement - The financial results will be discussed in a conference call scheduled for 8:00 a.m. Eastern Time on March 10, 2026, followed by a Q&A session [2]. - Interested parties can join the call by dialing 800-717-1738 or 646-307-1865 for international callers, using access code 81823 [2]. Group 2: Company Overview - Apyx Medical Corporation specializes in surgical aesthetics, offering products like Renuvion and the AYON Body Contouring System [3]. - The company’s Helium Plasma Platform Technology products provide controlled heat to tissue, supported by over 90 clinical documents [3]. - The AYON Body Contouring System is FDA-cleared and designed to integrate various surgical capabilities, enhancing body contouring treatments [3].

Core Viewpoint - Apyx Medical Corporation will participate in The Citizens Life Sciences Conference on March 11, 2026, showcasing its leadership in surgical aesthetics and innovative products [1][2]. Company Overview - Apyx Medical Corporation specializes in surgical aesthetics, offering products such as Renuvion and the AYON Body Contouring System™ [3]. - The company utilizes Helium Plasma Platform Technology, which provides controlled heat to tissue, enhancing surgical outcomes [3]. - Renuvion and J-Plasma are supported by over 90 clinical documents, demonstrating their effectiveness in cosmetic and hospital surgical markets [3]. - The AYON Body Contouring System is FDA-cleared and designed to integrate multiple surgical capabilities, empowering surgeons with a comprehensive treatment platform [3]. - Apyx Medical also engages in OEM agreements with other medical device manufacturers, leveraging its expertise in unique waveforms [3].

Core Insights - Apyx Medical Corporation is participating in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 10, 2026 [1] Company Overview - Apyx Medical Corporation specializes in surgical aesthetics, offering innovative products such as Renuvion and the AYON Body Contouring System [2] - The company utilizes Helium Plasma Platform Technology, which provides controlled heat to tissue, enhancing surgical outcomes [2] - Renuvion and J-Plasma are supported by over 90 clinical documents, demonstrating their effectiveness in both cosmetic and hospital surgical markets [2] - The AYON Body Contouring System is FDA-cleared and designed to integrate multiple functionalities, including fat removal and tissue contraction, into a single platform [2] - Apyx Medical also engages in OEM agreements with other medical device manufacturers, leveraging its expertise in unique waveforms [2]